LEADER 04015nam  22006375  450 
001 9910919814303321
005 20241225115231.0
010   $a9783031659485$b(electronic bk.)
010   $z9783031659478
024 7 $a10.1007/978-3-031-65948-5
035   $a(MiAaPQ)EBC31859404
035   $a(Au-PeEL)EBL31859404
035   $a(CKB)37081496800041
035   $a(DE-He213)978-3-031-65948-5
035   $a(EXLCZ)9937081496800041
100   $a20241225d2024      u|         0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aBiostatistics in Biopharmaceutical Research and Development $eClinical Trial Design, Volume 1 /$fedited by Ding-Geng Chen
205   $a1st ed. 2024.
210  1$aCham :$cSpringer Nature Switzerland :$cImprint: Springer,$d2024.
215   $a1 online resource (355 pages)
311 08$aPrint version: Chen, Ding-Geng Biostatistics in Biopharmaceutical Research and Development Cham : Springer,c2025 9783031659478 
327   $aBias and Randomization in Clinical Trials: 1980s ? 2020s ? 2060s -- The Markov Model for Survival Trials at 35 Years-Old -- Absolute Power Corrupts Absolutely: A Review of the Use of Unconditional Probabilities in the Planning of Clinical Trials -- Design of Clinical Trials with the Desirability of Outcome Ranking Methodology -- Benefit:Risk Assessments during Clinical Trials: A Prediction Approach Using the Desirability of Outcome Ranking (DOOR) -- The Power of Integration: How the 2-in-1 Clinical Trial Design is Changing the Future of Drug Development -- A Unified Bayesian Decision Rule-Based Approach for Bayesian Design of Clinical Trials Using Historical Data -- Group Sequential Design Under Non-proportional Hazards: Methodologies and Examples -- Multiple Testing in Group Sequential Design -- Plan per-protocol (PP) causal inference analysis addressing intercurrent events following the targeted learning roadmap -- Maximum Tolerated Imbalance Randomization: Theory and Practice -- Response-adaptive randomization designs based on optimal allocation proportion.
330   $aThe Deming Conference on Applied Statistics has long been deemed an influential event in the biostatistics and biopharmaceutical profession. It provides learning experience on recent developments in statistical methodologies in biopharmaceutical applications and FDA regulations. This book honors 80 years of contributions and dedication of the Deming Conference in biostatistics, and biopharmaceutical clinical trial methodology and applications. All chapters are contributed by world-class and prominent Deming speakers, who've contributed their cutting-edge research and developments to the community. Volume 1 covers Historical Milestones in Clinical Trial Design, FDA biopharmaceutical design guidance, and emerging development in Clinical Trial Design Methodology. This book aims to booster research, education, and training in biostatistics and in biopharmaceutical research and development.
606   $aBiometry
606   $aClinical medicine$xResearch
606   $aPublic health
606   $aSampling (Statistics)
606   $aData mining
606   $aBiostatistics
606   $aClinical Research
606   $aPublic Health
606   $aSurvey Methodology
606   $aData Mining and Knowledge Discovery
615  0$aBiometry.
615  0$aClinical medicine$xResearch.
615  0$aPublic health.
615  0$aSampling (Statistics).
615  0$aData mining.
615 14$aBiostatistics.
615 24$aClinical Research.
615 24$aPublic Health.
615 24$aSurvey Methodology.
615 24$aData Mining and Knowledge Discovery.
676   $a570.15195
700   $aChen$b Ding-Geng$0767993
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
912   $a9910919814303321
996   $aBiostatistics in Biopharmaceutical Research and Development$94306295
997   $aUNINA